Compare ADMA Biologics Inc (ADMA) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Marsh & McLennan Companies, Inc. — how do they compare? ADMA Biologics Inc trades at $9.87 (market cap $2.22B), while Marsh & McLennan Companies, Inc. trades at $188.83 (market cap $91.27B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 41.1× ADMA Biologics Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.07% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | MRSH | |
|---|---|---|
Market Cap | $2.22B | $91.27B |
Sector | Health | Financials |
52-Week High | $20.38 | $211.21 |
52-Week Low | $7.60 | $157.32 |
Enterprise Value | $2.29B | $111.95B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Marsh & McLennan (MRSH) trades at $190.79, down 0.45% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat estimates with EPS of $2.96 versus $2.88 expected, driven by 6% revenue growth. The company announced the acquisition of Accel to expand Midwest operations, enhancing its insurance and consulting services. Valuation metrics show a P/E of 23.35 and ROE of 25.72%, reflecting robust profitability.
Outlook remains positive with a consensus price target of $202.89, offering ~6% upside. Risks include margin pressure from rising expenses and soft P&C pricing. Institutional activity is mixed, with Bank of America reducing its stake while others like Ashton Thomas Securities added positions. The stock presents a growth opportunity amid strategic expansions, though investors should monitor expense management and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
